Clinical strains of Lactobacillus reduce the filamentation of Candida albicans and protect Galleria mellonella against experimental candidiasis

Rossoni, Rodnei Dennis; Velloso, Marisol dos Santos; Figueiredo, Lívia Mara Alves; Martins, Carolina Scanavez; Jorge, Antônio Olavo Cardoso; Junqueira, Juliana Campos

doi:10.1007/s12223-017-0569-9

Cited by 26 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from traditional antifungal compounds, there is also a growing interest in the use of probiotic bacteria as agents against C. albicans . In a recent study, the antifungal activity of clinical isolates of Lactobacillus strains were tested against C. albicans biofilms in vitro and it was shown that certain species of lactobacilli had an effect on C. albicans morphogenesis and biofilm formation 317 318 . Using the G. mellonella model system the same group showed that these probiotic bacteria reduce filamentation by C. albicans and also stimulate the host innate immune system, thereby protecting the host against C. albicans infections 319 .…”

Section: Methods For Monitoring In Vivo Performancmentioning

confidence: 99%

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Dijck¹,

Sjollema²,

Cammue³

et al. 2018

Microb Cell

View full text Add to dashboard Cite

Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

show abstract

Section: Methods For Monitoring In Vivo Performancmentioning

confidence: 99%

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Dijck¹,

Sjollema²,

Cammue³

et al. 2018

Microb Cell

View full text Add to dashboard Cite

show abstract

“…Besides, the number of anaerobic bacteria and abundance of Lactobacillus were all significantly reduced in ABX mice. However, a decrease in anaerobic bacteria could promote overgrowth of Candida glabrata [73], Lactobacillus crispatus could modulate epithelial cell defense against C. albicans [65], clinical strains of Lactobacillus could influence the growth and expression of C. albicans virulence factors [58], and the metabolites of L. gasseri and L. crispatus could downregulate biofilm formationrelated genes of C. albicans, thus inhibiting biofilm formation of C. albicans [59]. These previous studies suggest that we should explore in detail the specific mechanisms by which members of the intestinal microbiota communicate with the host immune system and identify specific species as different members of intestinal microbiota elicit different immune responses relating to itself or its metabolites.…”

Section: Discussionmentioning

confidence: 99%

“…Lachnospiraceae abundance was decreased in a model of ulcerative colitis [57]. Lactobacillus could reduce the virulence of C. albicans [58], and its metabolites inhibit C. albicans biofilm formation [59]. In summary, there were significant changes in intestinal microbiota structure between ABX and CNV mice, and the significant discrepant bacteria may play a key role during invasive candidiasis in mice and further study is required to explore the specific bacteria which actually work during invasive candidiasis.…”

Section: Overall Intestinal Microbiota Structure Was Changed In Abx Micementioning

confidence: 99%

Microbiota-driven interleukin-17 production provides immune protection against invasive candidiasis

et al. 2020

Crit Care

View full text Add to dashboard Cite

Background: The intestinal microbiota plays a crucial role in human health, which could affect host immunity and the susceptibility to infectious diseases. However, the role of intestinal microbiota in the immunopathology of invasive candidiasis remains unknown. Methods: In this work, an antibiotic cocktail was used to eliminate the intestinal microbiota of conventionalhoused (CNV) C57/BL6 mice, and then both antibiotic-treated (ABX) mice and CNV mice were intravenously infected with Candida albicans to investigate their differential responses to infection. Furthermore, fecal microbiota transplantation (FMT) was applied to ABX mice in order to assess its effects on host immunity against invasive candidiasis after restoring the intestinal microbiota, and 16S ribosomal RNA gene sequencing was conducted on fecal samples from both uninfected ABX and CNV group of mice to analyze their microbiomes. Results: We found that ABX mice displayed significantly increased weight loss, mortality, and organ damage during invasive candidiasis when compared with CNV mice, which could be alleviated by FMT. In addition, the level of IL-17A in ABX mice was significantly lower than that in the CNV group during invasive candidiasis. Treatment with recombinant IL-17A could improve the survival of ABX mice during invasive candidiasis. Besides, the microbial diversity of ABX mice was significantly reduced, and the intestinal microbiota structure of ABX mice was significantly deviated from the CNV mice. Conclusions: Our data revealed that intestinal microbiota plays a protective role in invasive candidiasis by enhancing IL-17A production in our model system.

show abstract

“…Various members of the human microbiota have been shown to produce inhibitors of 344 C. albicans hypha formation or virulence 13,14,16 . Often the actual inhibitory molecule is not 345 known and constitutively produced [41][42][43] . These observations suggest that bacteria inhabiting 346 the gastrointestinal tract along with C. albicans may utilize an inhibitory strategy to enhance 347 their ability to co-exist with C. albicans in their common niche.…”

Section: Damage 318mentioning

confidence: 99%

A synthetic system that senses Candida albicans and inhibits virulence factors

Tscherner

Giessen

Markey

et al. 2018

Preprint

View full text Add to dashboard Cite

19Due to a limited set of antifungals available and problems in early diagnosis invasive fungal 20 infections caused by Candida species are among the most common hospital-acquired 21 infections with staggering mortality rates. Here, we describe an engineered system able to 22 sense and respond to the fungal pathogen Candida albicans, the most common cause of 23 candidemia. In doing so, we identified hydroxyphenylacetic acid (HPA) as a novel molecule 24 secreted by C. albicans. Furthermore, we engineered E. coli to be able to sense HPA 25 produced by C. albicans. Finally, we constructed a sense-and-respond system by coupling 26 the C. albicans sensor to the production of an inhibitor of hypha formation thereby reducing 27 filamentation, virulence factor expression and fungal-induced epithelial damage. This system 28 could be used as a basis for the development of novel prophylactic approaches to prevent 29 fungal infections. 30 31 32 Introduction 33 Fungal pathogens cause diverse types of infections ranging from superficial to systemic and 34 claim about 1.5 million lives per year 1 . Candida species are among the most common 35 opportunistic fungal pathogens and represent the fourth-leading cause of hospital-acquired 36bloodstream infections with mortality rates of more than 40% in immunocompromised 37 patients 1-4 . 38Candida albicans represents the main cause of candidemia, being responsible for 39 more than 40% of all cases worldwide 2 . C. albicans is a commensal colonizing the 40 gastrointestinal and genitourinary tracts of healthy individuals 5 . However, under 41 immunocompromised conditions, C. albicans can penetrate epithelia and cause severe 42 systemic infections 6 . A key virulence factor of C. albicans is its morphologic plasticity; it can 43 reversibly switch between a yeast and a filamentous or true hyphal morphology depending on 44 the environmental conditions. On epithelial surfaces, initial adhesion and subsequent 45 filamentation are required for efficient epithelial penetration 7 . In addition, several virulence 46 factors such as Candidalysin, a peptide that damages epithelial cells, are produced 47 exclusively by the hyphal form 8 . 48Difficulties associated with rapid and reliable diagnosis as well as lack of specific 49 disease manifestations contribute to the high mortality rates of systemic fungal infections 9 . 50Antifungal prophylaxis is currently applied to high risk individuals. While effective in preventing 51 Candida infections 10,11 , prolonged prophylaxis can lead to the emergence of resistant strains 52 or to an increase of species, that are intrinsically resistant to the limited set of antifungals 53 available 10,12 . Development of novel antifungals with fungistatic or fungicidal activity is limited 54 by the relative dearth of specific targets in these eukaryotic pathogens. Thus, more recently 55 approaches targeting specific virulence factors have been gaining interest. This strategy can 56 increase the number of potential targets, that are specific to the pathogen, and will...

show abstract

Clinical strains of Lactobacillus reduce the filamentation of Candida albicans and protect Galleria mellonella against experimental candidiasis

Cited by 26 publications

References 38 publications

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Microbiota-driven interleukin-17 production provides immune protection against invasive candidiasis

A synthetic system that senses Candida albicans and inhibits virulence factors

Contact Info

Product

Resources

About